LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant ...
H.C. Wainwright downgraded Pliant Therapeutics (NASDAQ:PLRX) stock from Buy to Neutral following concerns about the safety of ...
Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...
Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...
Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback